No signal change: HOLD / HOLD / HOLD holds at every horizon. Price is -2.9% to $1,113.30, extending the fade off the $1,249 all-time high. The valuation verdict got firmer, not softer: the 10-Year Treasury rose 4.50% → 4.75%, which pulls the warranted P/E down 23× → 22×, so the actual/warranted ratio widened 1.39× → 1.44× despite the lower price — still Expensive, double-confirmed (ratio ≥ 1.40 and actual ~31.8× ≥ the 22× Health-Care floor). The Valuation Ceiling gate continues to cap all three horizons at Hold.
Eli Lilly and Company is one of the world's largest pharmaceutical firms, founded in 1876 and headquartered in Indianapolis. Its economics are now dominated by the incretin (GLP-1) franchise — tirzepatide, sold as Mounjaro for type-2 diabetes and Zepbound for obesity — which sits alongside a deep portfolio in diabetes (Jardiance, Trulicity), oncology (Verzenio), immunology (Taltz, Olumiant) and neuroscience (Kisunla for Alzheimer's). What sets Lilly apart is the combination of the highest-growth product cycle in large-cap pharma with an unusually durable, long-dated patent estate and a first-mover lead in oral GLP-1 via orforglipron (branded Foundayo). For a reader, think of it as the branded-drug leader of the obesity/diabetes super-cycle: enormous, highly profitable, growing revenue faster than 50% year-on-year, but priced by the market as a premium compounder.
Lifecycle & sector: Health Care / Drug Manufacturers — General, classified Mature-but-accelerating large-cap pharma. Revenue is compounding at large-growth rates (Q1 2026 revenue $19.8bn, +55% YoY) on the tirzepatide ramp, so we score it on the pharma profile (R&D efficiency, patent-cliff exposure, pipeline depth, ROIC) with growth-stage emphasis on the top line.
| Sub-signal | Value | Read | Score |
|---|---|---|---|
| Revenue trajectory | +55% YoY (Q1'26 $19.8bn); FY25 $63.9bn → FY26e $85.3bn | Best-in-class growth for a $1tn-cap pharma | 95 |
| Profitability vs peers | Gross margin 83.5%, operating margin 45.9%, net margin 35% | Top-decile pharma margins, expanding on scale | 90 |
| Cash generation | TTM FCF ~$9.2bn; FCF/share ~$15; heavy capacity capex | Real but FCF conversion depressed by plant build-out | 62 |
| Balance-sheet health | Net debt ~$38bn / EBITDA ~$29bn ~1.3×; interest cover ~37×; current 1.5 | Investment-grade, comfortably serviced | 80 |
| R&D efficiency / pipeline | Orforglipron (oral GLP-1, launched), retatrutide (next-gen tri-agonist), Kisunla, lepodisiran | Deepest incretin pipeline in the industry | 90 |
Branded incretins price well, but MFN/Medicare policy caps the ceiling
N/A for pharma (neutral)
Scripts move on efficacy/access/price — patient stickiness is moderate
Vast manufacturing scale-up; a supply, not cost, war
Deep, long-dated patent estate + brand — the core moat
Moat = average ≈ 69/100. The wall is the patent estate; switching costs and cost advantage are trimmed by the live two-horse race below.
| Rival | Threat | Share trajectory | Moat-erosion vector |
|---|---|---|---|
| Novo Nordisk (semaglutide — Wegovy/Ozempic, oral sema) | Direct #1 rival | Lilly gaining (efficacy + oral lead); Novo's ZEUS CV trial failed 31 Jul | Oral-semaglutide access/price pressure on the oral segment |
| Amgen (MariTide, monthly injectable) | Next-gen entrant | Pre-launch; mixed Phase 2/3 tolerability | Convenience (monthly dosing) if data holds |
| Viking Therapeutics (VK2735, oral + injectable) | Emerging biotech | Phase 3; takeout candidate | Fast-follower efficacy in a widening TAM |
| Roche (CT-388 / Carmot assets) | Deep-pocketed late entrant | Early clinical | Capital + commercial reach over a multi-year horizon |
→ Net effect on the moat: Switching Costs trimmed to 55, Cost Advantage to 62 (a supply-and-access race, not a monopoly). Intangibles (patents) carry the score. Competitive threat level: elevated — propagated to the §11 Bear trigger and the §12 thesis-invalidation rule.
ROIC sits in the top decile of pharma (est. ~30%+, FMP ROE/ROA sub-scores both a maximal 5/5). Capital allocation is disciplined-aggressive: heavy reinvestment into manufacturing capacity and a steady bolt-on M&A cadence (e.g. the ~$2.8bn AtaiBeckley psychedelics deal, Jul 2026) — these IPR&D charges depress reported TTM EPS but are the right long-run use of cash. Dividend ~0.6% yield, payout ~22% — ample cover. Quality score: 84/100.
Lilly is an elite business at an Expensive price — the pillar the anchor exists to keep honest. We score the actual multiple against a computed warranted multiple, not against Lilly's own (rich) history.
| Lens | Value | Read |
|---|---|---|
| Warranted-multiple anchor (40%) | 1.44× warranted | Expensive |
| Sector median P/E (20%) | ~31.8× fwd vs pharma ~16-18× | Well above the group |
| Own-history decile (15%) | Off the $1,249 ATH but multiple still upper-range | Rich vs own 5-yr band |
| PEG (10%) | clean PEG ~1.45 | Fair-to-full on growth — growth is real, but priced |
| Analyst consensus (15%) | Price ~18% below $1,315 consensus / $1,300 median | Street sees upside — the one bullish cross-check |
FCF yield (universal anchor): ~$9.2bn FCF / ~$1.04tn EV ≈ 0.9% — sub-1%, i.e. very expensive on cash; the buyer is paying for future growth, and capacity capex is currently suppressing FCF.
Reverse-DCF read: at $1,113 the market embeds ~13-15% durable long-run EPS growth; our disciplined estimate is ~10% — the price already assumes Lilly executes near-flawlessly. That gap is why the pillar is Expensive even after an 11% pullback.
Analyst cross-check: consensus target $1,315.42 (high $1,500 / median $1,300 / low $1,135), ~18% above spot; grades 33 Buy / 9 Hold / 3 Sell (73% bullish, "Buy" consensus); FMP health rating B (ROE/ROA 5/5, but P/E and P/B sub-scores 2/1 — the rating agrees the balance sheet is elite and the price is steep). The anchor is supreme: these relative lenses order the name within Expensive; they cannot lift it out. Valuation score: 37/100.
Primary driver: the GLP-1 / obesity & diabetes super-cycle, with US drug-pricing policy (IRA / MFN) as the offsetting secondary driver. Lilly's revenue trajectory is levered almost entirely to how fast the incretin market expands and how much of it Lilly keeps.
| Horizon | Read | Assessment |
|---|---|---|
| Historical (25%) | Tirzepatide from launch to ~$18bn+ run-rate; oral GLP-1 market ~35% CAGR to 2035 | Powerful, sustained tailwind |
| Current (50%) | Orforglipron launched and leading the oral segment; Novo's ZEUS CV trial failed (31 Jul); duopoly ~87% of revenue | Tailwind — Lilly gaining share; policy overhang the only brake |
| Forward (25%) | Retatrutide behind it; label/geographic expansion; offset by MFN + Medicare negotiation risk | Structurally positive, policy-capped |
Driver score: 80/100 — Strong Tailwind, eligible to amplify a BUY to STRONG BUY. It does not here: the base signal is HOLD (Valuation Ceiling), and HOLD never amplifies. Thesis-invalidation floor: the case breaks if a rival takes durable tirzepatide/oral share, or if MFN/Medicare pricing materially compresses US incretin economics.
The 30 Jul Macro-Economic report downgraded Health Care (XLV) from Outperform across the board to N / N / O (Neutral short & medium, Outperform long) under a "stagflation-lite" regime. Pharma is defensive and low macro-sensitivity, so the economy is neither a clear tailwind nor a headwind here — pressure Neutral. That leaves the base signal unchanged (a Neutral pressure enables no amplification). The one macro tail that is armed — the S&P-500 AI-concentration unwind — does not apply to Lilly: its earnings are clean (not non-operating-inflated) and it is not in the AI cohort, so it inherits no cohort de-rating leg.
Source: sector-map (XLV) · Macro report 2026-07-30
Momentum has rolled over into the print. The higher timeframes are still up, but the daily and intraday charts are bearish — confluence is bearish (short-term).
| Sub-signal | Read | Score |
|---|---|---|
| MTF trend confluence | Monthly/weekly up; daily weakening (RSI 41, MACD histogram negative); hourly/15-min strong downtrend | 55 |
| Risk-reward / position-risk | Price $1,113; nearest support $1,079/$1,052, 200-DMA $1,026; stop ~1 ATR ($37.6) below | 50 |
| Relative strength | -11% off the $1,249 ATH over ~6 weeks; modestly lagging a firm XLV recently | 48 |
| Macro overlay (low sensitivity, 10%) | Pharma is macro-defensive; XLV short-signal Neutral | 48 |
| Sentiment (analyst grades + news) | July target hikes (UBS/Guggenheim/Truist/BofA/JPM); all grades "maintain" Buy; Novo stumble a relative positive | 60 |
| Catalysts (Q2 tomorrow) | One dominant, imminent binary event — high path risk | 45 |
Timing score: 53/100 — Neutral, softening. Confidence capped at 40% by the Earnings Event Risk gate: you cannot honestly grade the near-term tape the day before a Lilly print.
| Date | Event | Impact | Forecast | Previous | Relevant? | Why |
|---|---|---|---|---|---|---|
| ~2026-08-05 | LLY Q2 2026 earnings (BMO, company event) | High | EPS ~$6.06 · Rev ~$20.7bn | — | Yes | The binding catalyst — incretin revenue, oral-script ramp, FY guide; LLY gaps hard on these |
| 2026-08-01 | US tariff wall deadline | High | — | — | Low | Broad-market/regime; indirect for defensive pharma |
| ~2026-08-12 | US CPI (Jul) | High | — | — | Low | Pharma is low macro-sensitivity; matters only via broad rates |
| Date | Event | Actual | Forecast | Surprise | Impact |
|---|---|---|---|---|---|
| 2026-07-31 | Core PCE (Jun) | 0.3% | 0.3% | In line | Neutral for pharma; kept the Fed on-hold narrative |
| 2026-07-31 | Novo Nordisk ZEUS CV trial | Fail | — | Negative for Novo | Relative positive for Lilly's competitive standing |
One event dominates the next fortnight and it is company-specific: Q2 earnings tomorrow, 5 Aug, before the open. Lilly is low macro-sensitivity, so the tariff/CPI cluster is background noise for this name — the print is everything. That is exactly why the report schedules its own next refresh for the trading day after.
| Timeframe | Trend | Direction | RSI | MACD | Key S/R | Breakout | Vol |
|---|---|---|---|---|---|---|---|
| Monthly | Uptrend ↑ | Bullish | 61 | +, rising | S: 972 · R: 1134 | Resistance breakout | 0.07× |
| Weekly | Uptrend ↑ | Bullish | 55 | +, flat | S: 977 · R: 1249 | Resistance breakout | 0.37× |
| Daily | Weakening → | Neutral-bearish | 41 | −, rolling over | S: 1079/1052 · R: 1149/1189 | None | 1.23× |
| Hourly | Strong down ↓ | Bearish | 32 | −, basing | S: 1109 · R: 1135 | Support breakdown | 1.13× |
| 15-min | Strong down ↓ | Bearish | 39 | − | S: 1109 · R: 1136 | Support breakdown | 0.09× |
| Confluence: Bearish (short-term) · MTF Score 55 | |||||||
The secular (monthly/weekly) uptrend is fully intact — price is far above the rising longer-term averages and printed fresh monthly-scale highs in early July. But the tactical picture has turned: the daily is below its 20- and 50-day averages (SMA50 ~$1,149) with a negative MACD, and both intraday frames are in a strong downtrend into the print. This is a textbook pullback within a larger uptrend — not a broken chart, but not a place to chase a long the day before earnings. The line in the sand is the 200-DMA (~$1,026) / $1,052 shelf.
6-month daily close with trailing SMA50. Ran to a $1,249 ATH in early July, then faded ~11% into the Q2 print; holding above the 200-DMA (~$1,026).
Q2 beats and management raises FY guidance on the tirzepatide + orforglipron ramp; oral-GLP-1 scripts surprise to the upside and the drug-pricing overhang stays contained. The multiple holds ~30× on higher forward EPS. ~+33% from spot.
An in-line-to-modest-beat quarter; the franchise keeps compounding but the rich multiple caps re-rating. Converges toward the ~$1,300 analyst median over 12 months as EPS grows into the price. ~+17%.
A Q2 miss or soft guide (script/inventory timing, a pricing headline, or oral-launch friction) meets an Expensive multiple — compression toward ~25× FY26 EPS, near the $850-880 analyst low. Competitive trigger: Novo's oral semaglutide or a next-gen entrant takes durable share. ~-19%. Note the binary risk is tomorrow.
Probability-weighted fair value ≈ 0.20×1,480 + 0.55×1,300 + 0.25×900 = ~$1,236 — above spot, but the distribution is wide and front-loaded onto tomorrow's print, which is precisely why the signal waits rather than acts.
Forecast: Fundamental: requires a pullback into ~$1,050-1,075 — reachable only on a weak print or broad de-rate; not imminent at $1,113. Technical: a reclaim of the $1,149 50-day is ~3-5% away and depends on tomorrow's reaction (catalyst-dependent, not time-projectable); the pullback-to-support branch triggers on a tested bounce off $1,052-$1,079. Catalyst: resolves tomorrow, 5 Aug — a >+5% beat-and-raise reaction on heavy volume would open the Catalyst path immediately. Overall: WAIT — the honest move is to let the print clear (the report re-runs 6 Aug) rather than position into a binary event on a name already capped at HOLD by valuation.
Forecast: No exit rule is live. The stop ($1,045) is ~6% below spot and just above the 200-DMA; a break would most plausibly come from a bad print tomorrow. This is a HOLD, not a position to exit — there is nothing mechanical to act on.
What you're risking: the drop to the $1,045 stop (-6%) and, if Q2 disappoints, the bear path to ~$900 (-19%) as an Expensive multiple compresses. Three entry conditions are unmet — you'd be buying above the fair-value entry zone, below the 50-day, and the day before earnings. Path risk is maximal.
What you're gaining: immediate participation in a best-in-class compounder — base upside to ~$1,300 (+17%) and bull to ~$1,480 (+33%), plus the retatrutide/CNS optionality you'd own for free. But the FCF yield (~0.9%) pays you almost nothing to wait.
Read: acting now is a coin-flip on a print, on a name already capped at HOLD by valuation. Waiting for the print to clear (or a pullback into $1,050-1,075) materially improves the deal.
What you're giving up: the base-case climb to ~$1,300 (+17%), the compounding of a 50%-plus revenue grower, and the pipeline optionality — and you'd be selling at roughly probability-weighted fair value (~$1,236), not below it.
What you're protecting: capital if tomorrow's print goes wrong (bear -19%). But no mechanical exit is live — stop clear, thesis intact, profit-target not hit. Selling here is a valuation-discipline call, not a rules call.
Read: for a holder this is a hold — trim only into strength toward $1,300. For a non-holder it is a wait, not a short.
Position sizing not computed — no risk budget or portfolio role was specified for this batch refresh. For context only: beta ~0.5 (LLY is low-beta vs the market), daily ATR ~$37.6 (~3.4% of price), and the stock has drawn down ~11% from its July ATH. The §12 Conviction Ladder reads Wait (0 of 3 entry paths open), so the sizing guidance is simply: watch the $1,050-1,079 support and let tomorrow's print resolve before committing capital.
{
"ticker": "LLY",
"date": "2026-08-04",
"version": "v6",
"brand": "",
"company": "Eli Lilly and Company",
"currency": "USD",
"exchange": "NYSE",
"exchange_ticker": "NYSE:LLY",
"isin": "US5324571083",
"api_ticker": "LLY",
"analysis_status": "on-going",
"lifecycle_stage": "large_cap_pharma_accelerated_growth",
"sector": "Health Care",
"gics_sector": "Health Care",
"country": "United States",
"finder_ticker": "LLY",
"user_horizon": null,
"user_allocation_pct": null,
"portfolio_role": null,
"price_at_rating": 1113.3,
"signal_short": "HOLD",
"signal_medium": "HOLD",
"signal_long": "HOLD",
"primary_signal": "HOLD",
"short_hold_reason": "expensive",
"short_cap_reason": null,
"quality_score": 84,
"valuation_score": 37,
"timing_score": 53,
"driver_score": 80,
"quality_detail": {
"industry_benchmark_name": "R&D Efficiency + Patent-Cliff Exposure (pharma)",
"industry_benchmark_value": 88,
"industry_benchmark_score": 88,
"moat_score": 69,
"roic_percentile_vs_peers": 92,
"capital_allocation": 78,
"management_skin_in_game": 60
},
"valuation_detail": {
"fcf_yield": 0.9,
"implied_growth_rate": 14.0,
"consensus_growth_rate": 29.0,
"historical_valuation_decile": 8
},
"timing_detail": {
"mtf_confluence": 55,
"risk_reward_score": 50,
"relative_strength_vs_spy": -3.0,
"relative_strength_vs_sector": -4.0,
"catalyst_clustering_score": 50,
"dynamic_macro_weight": 0.1
},
"economic_alignment_stance": "Neutral",
"economic_alignment_conviction": 55,
"economic_alignment_pressure": "Neutral",
"economic_alignment_source": "sector-map",
"macro_report_date": "2026-07-30",
"economic_alignment_sector": "Healthcare (XLV) s=N / m=N / l=O",
"overall_confidence": 40,
"val_band": "expensive",
"warranted_multiple": 22,
"actual_multiple": 31.8,
"warranted_ratio": 1.44,
"val_multiple_basis": "clean forward FY26 P/E ~31.8x; TTM 39.5x (IPR&D-depressed)",
"discount_rate_r": 9.25,
"risk_free_10y": 4.75,
"g_near": 10,
"g_term": 3,
"clean_pe": 31.8,
"clean_peg": 1.45,
"nonop_pct_of_net_income": -8,
"fcf_yield_pct": 0.9,
"moat_score": 69,
"roic_percentile_vs_peers": 92,
"industry_benchmark_name": "R&D Efficiency + Patent-Cliff Exposure (pharma)",
"industry_benchmark_score": 88,
"competitive_share_trajectory": "gaining",
"competitive_threat_level": "elevated",
"fair_value_est": 1075,
"stop_loss": 1045,
"target_price": 1300,
"scenario_base_target": 1300,
"scenario_bull_target": 1480,
"scenario_bear_target": 900,
"entry_groups_met": 0,
"entry_conviction": "Wait",
"exit_groups_live": 0,
"exit_action": "Hold",
"short_entry_confirmed": false,
"hard_gate_state": "caution",
"gates_triggered": [
"Valuation Ceiling",
"Earnings Event Risk"
],
"gates_caution": [
"US drug-pricing (MFN/Medicare) overhang",
"Elevated GLP-1 competition (Novo oral semaglutide)"
],
"do_not_buy_triggers": [],
"analyst_consensus_target": 1315.42,
"analyst_target_high": 1500,
"analyst_target_low": 1135,
"analyst_target_median": 1300,
"analyst_target_upside_pct": 18.2,
"analyst_grades_consensus": "Buy",
"analyst_bullish_pct": 73.3,
"analyst_coverage_count": 45,
"recent_upgrades_30d": 0,
"recent_downgrades_30d": 0,
"fmp_rating": "B",
"fmp_overall_score": 3,
"next_update_date": "2026-08-06",
"next_update_basis": "Q2 2026 earnings 5 Aug (BMO) +1 trading day",
"prior_report": "calibration-LLY-20260720-1810.json",
"prior_primary": "HOLD",
"changes_note": "HOLD/HOLD/HOLD held. Price -2.9% to $1,113.30. 10-Y 4.50->4.75 pulled warranted P/E 23->22 and widened actual/warranted 1.39->1.44 (MORE expensive despite lower price) -> Valuation Ceiling still binds, now double-confirmed. Economic Alignment downgraded Tailwind->Neutral (XLV O/O/O->N/N/O). Timing 56->53 (confluence bearish). Earnings Event Risk gate now live (Q2 prints 5 Aug BMO) -> overall confidence 58->40. Competitive tailwinds: Novo ZEUS trial failed 31 Jul; orforglipron leads oral GLP-1. Entry Wait; next update 6 Aug post-print."
}
HOLD across all three horizons, unchanged from 20 Jul. The signal is set by the Valuation Ceiling gate (Expensive, 1.44× warranted) — a great business at a rich price — with the Earnings Event Risk gate emptying the near-term timing edge into tomorrow's Q2 print. Next refresh 6 Aug, the day after earnings.